OBJECTIVE： To prepare paclitaxel（PTX） and curcumin （CUR） chemically conjugated gold nanorod （GNR） （PTX/CUR-BPGNR）， and to preliminarily study its anti-multidrug-resistant（MDR） tumor effect in vitro and mechanisms. METHODS： GNR was prepared by seed growth method and modified with biotin-polyethylene glycol （Biotin-PEG） to obtain BPGNRs. Lipoic acid PTX and CUR （PIXLA and CURLA） were synthesized； 1H-NMR and MS were used to confirm their chemical structures. PTXLA and CURLA were connected to BPGNR surface to obtain PIX and CUR-bonding BPGNR （PTX/CUR-BPGNR） via strong binding of Au-S bond. The morphology of PTX/CUR-BPGNR was observed， and drug-loading amount and in vitro drug release were investigated （under near-infrared illumination and esterase condition）. Adriamycin （ADR） MDR breast cancer MCF-7/ADR cells were selected as research objects， and MTT assay was used to investigate the survival rate of cells after treated with BPGNR， PTX， CUR， PTX/CUR mixture and PTX/CUR-BPGNR， and ELISA was used to detect the expression of P-gp. RESULTS： PTX/CUR-BPGNR was prepared successfully with uniform size and shape. The maximum absorption wavelength was 808 nm， and drug-loading amount of PTX and CUR were 16.1％ and 8.4％， respectively. The preparations were given near-infrared illumination and esterase to promote the release of PTX and CUR. 64 h accumulative drug release rates were 37.2％ and 39.1％. Survival rates of MCF-7/ADR cells after treated with BPGNR， PTX， CUR and PTX/CUR mixture， PTX/CUR-BPGNR were 95.8％， 71.2％， 91.9％， 45.8％ and 22.5％， respectively. The relative expressions of P-gp in cells were 105.6％， 75.2％， 73.8％， 51.7％， respectively. CONCLUSIONS： PTX/CUR-BPGNR is successfully prepared and can improve the ability of CUR inhibiting the expression of P-gp so as to strengthen its anti-MDR effects.